Your browser doesn't support javascript.
loading
Potential values of circulating tumor cell for detection of recurrence in patients of thyroid cancer: a diagnostic meta-analysis.
Liang, Ming-Xing; Fei, Yin-Jiao; Yang, Kai; Tang, Wen-Juan; Cao, Xin-Hui; Tang, Jin-Hai.
Afiliación
  • Liang MX; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
  • Fei YJ; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
  • Yang K; School of Clinical Medicine, Xuzhou Medical University, 221000, Xuzhou, P.R. China.
  • Tang WJ; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China.
  • Cao XH; School of Clinical Medicine, Xuzhou Medical University, 221000, Xuzhou, P.R. China.
  • Tang JH; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, P.R. China. jhtang@njmu.edu.
BMC Cancer ; 22(1): 954, 2022 Sep 05.
Article en En | MEDLINE | ID: mdl-36064384
BACKGROUND: Several studies have reported that circulating tumor cells (CTCs) are a promising marker for the diagnosis of thyroid cancer (TC) with recurrence or distant metastasis (DMs). However, some studies emerged with conflicting results. Therefore, we provide a meta-analysis to evaluate the diagnostic performance of CTC for detection of recurrence in patients of TC. METHODS: We searched PubMed, Web of Science, Cochrane library with the keywords "thyroid cancer" and "circulating tumor cells". Data extraction and risk of bias assessment were performed independently by two reviewers. The summary receiver operating characteristic curve (SROC) and other parameters were adopted to summarize the overall test performance. The sensitivity of CTCs in the detection of recurrent TC was reviewed. All analyses were performed by STATA 12.0 and Meta-disc software. RESULTS: For CTCs expressing epithelial cell adhesion molecule (EpCAM), seven studies were included in our meta-analysis. Pooled sensitivity, specificity, and diagnostic odds ratio were 0.71 (95% CI: 0.63-0.78), 0.89 (95% CI: 0.84-0.94), and 26.75 (95% CI: 9.11-78.53); 0.78 (95% CI: 0.65-0.89), 0.88 (95% CI: 0.76-0.96), and 40.01 (95% CI: 10.49-152.63) for CTCs expressing thyroid stimulating hormone receptor (TSHR). The area under the SROC for EpCAM and TSHR were both 0.91. CONCLUSION: CTC was a reliable marker for the diagnosis of TC patients with recurrence and DMs, and the sensitivity of CTCs expressing TSHR was higher than that of EpCAM. Additional research is warranted in order to establish uniformity in international guidelines, make up the drawbacks of conventional diagnostic methods and to prevent futile surgery.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Células Neoplásicas Circulantes Tipo de estudio: Diagnostic_studies / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Células Neoplásicas Circulantes Tipo de estudio: Diagnostic_studies / Guideline / Systematic_reviews Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido